---
layout: default
title: Pembrolizumab
parent: 僅模型預測 (L5)
nav_order: 519
evidence_level: L5
indication_count: 10
---

# Pembrolizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Pembrolizumab: From Unspecified Original Indication to Gingival Fibromatosis

## One-Sentence Summary

Pembrolizumab (DrugBank DB09037) is an anti-PD-1 immune checkpoint inhibitor; its original approved indication is not recorded in this evidence pack, and detailed mechanism-of-action data is also missing. The TxGNN model's top-ranked candidate for repurposing is **Gingival Fibromatosis**, with a prediction score of **99.40%**, but this candidate currently has **0 clinical trials** and **0 publications** supporting it, and the evidence pack's own mechanistic review found no biological link between PD-1/PD-L1 blockade and this benign condition.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — no original indication or product licence data on file |
| Predicted New Indication | Gingival Fibromatosis (fibromatosis, gingival) |
| TxGNN Prediction Score | 99.40% |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available for pembrolizumab in this evidence pack. Based on the literature captured elsewhere in this pack, pembrolizumab is known to act as a monoclonal antibody that blocks the PD-1 receptor, restoring T-cell-mediated anti-tumour immunity in malignancies with immune evasion (e.g. non-small-cell lung cancer, melanoma).

Gingival fibromatosis, however, is a benign, non-immunogenic overgrowth of gingival fibrous connective tissue, typically driven by hereditary fibrotic pathways rather than tumour-immune evasion. The evidence pack's own mechanistic assessment explicitly states there is **no known association** between PD-1/PD-L1 checkpoint blockade and this condition.

This candidate therefore represents a case where the TxGNN model assigned a high similarity score, but neither the underlying biology nor any external evidence currently supports the prediction. It should be treated as a model-generated hypothesis only, not as a validated repurposing signal.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

Currently no related literature available

## Cytotoxicity

Pembrolizumab is an antineoplastic agent (immune checkpoint inhibitor), as evidenced by the drug-review and oncology trial literature captured elsewhere in this evidence pack (e.g. PMID [27398650](https://pubmed.ncbi.nlm.nih.gov/27398650/), "Pembrolizumab (Keytruda)").

| Item | Content |
|------|------|
| Cytotoxicity Classification | Immunotherapy (anti-PD-1 checkpoint inhibitor) |
| Myelosuppression Risk | Please refer to the Product Information (PI) warnings and precautions |
| Emetogenicity Classification | Please refer to the Product Information (PI) warnings and precautions |
| Monitoring Items | Please refer to the Product Information (PI) warnings and precautions |
| Handling Protection | Please refer to the Product Information (PI) warnings and precautions |

## Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked candidate (Gingival Fibromatosis) has no clinical trial or literature support, and the evidence pack's own mechanistic analysis finds no biological rationale for immune checkpoint blockade in this benign, non-immunogenic condition. Pembrolizumab is also not currently marketed in this jurisdiction, and a blocking data gap on local product-label warnings/contraindications (DG001) prevents any safety-tier assessment. Note: all 10 TxGNN-ranked candidates in this evidence pack (including anatomically plausible ones such as lung hilum carcinoma and pulmonary sulcus neoplasm) were independently scored "Hold" — none currently clear an evidence threshold beyond model prediction alone.

**To proceed, the following is needed:**
- Local product-label warnings and contraindications (DG001, Blocking) — required before any S1 safety review can begin
- Verified mechanism-of-action data from DrugBank (DG002)
- Original approved indication(s) and regulatory history for pembrolizumab
- If pursuing repurposing further, prioritise candidates with class-level mechanistic plausibility and disease-specific evidence (e.g. lung hilum carcinoma, lung germ cell tumour) over candidates like gingival fibromatosis that lack any supporting rationale
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

